Interview with Günter Cseh, General Manager, Meda Pharma Austria
What have been the most significant developments as a result of the acquisition of Viatris by Meda Pharma in 2005? At that time Viatris was a small company, and there…
Address: Guglgasse 15/II. Stock, 1110 Vienna,Austria
Tel: +43 + (1) 86390-0
Web: http://www.meda.at/content/home/index.php
Meda is a leading specialty pharmaceutical company in Europe that offers cost-oriented medicine and the medical need. With offices in 26 countries Meda covers almost the whole of Europe. In other world markets, the pharmaceuticals are marketed by Meda and other representatives of pharmaceutical companies and sold.
Meda focuses on the treatment areas asthma & allergies, cardiovascular disease, pain and inflammation, gastroenterology and dermatology & infections.
Meda Pharma GmbH with its headquarters in Vienna (see photo) is a subsidiary of Meda AB., Sweden. Meda Pharma Austria looks back on a long company history, what with the PANCHEMIE HOMBURG found its founding. Subsequently developed into ASTA MEDICA Arzneimittel GmbH, which was renamed in 2002 in VIATRIS Pharma GmbH and since October 2005, owned by the Swedish pharmaceutical company Meda is.
Meda Pharma GmbH Austria continues its focus on products for the therapy and treatment of respiratory diseases (Novolizer ®, Allergodil ®), pain (Adamon ®) for the prevention and treatment of osteoporosis (Maxi-Kalz ®), treatment of cardiovascular disease (Magnosolv ®, Aquaphoril ®) and a specific complication of diabetes mellitus (Thioctacid ®), as well as therapeutic agents for use in the Department of Gynecology (Cyklokapron ® Ftbl., Estrogel ®, Utrogestan ®, Parlodel ®). Another therapeutic area of Meda Pharma, the treatment of skin diseases, such as the actinic keratoses, basal cell carcinomas or genital warts (Aldara ®). The innovative nutritional supplements Longeva ® completes the product range.
Furthermore, there are good pharmacy products such as Ce-soda ®, Histaxin ®, and Kamillosan Travelgum ® and the dietary supplement Osteo-Active ® and Magnofit ® – pellets in the product portfolio of Meda Austria.
What have been the most significant developments as a result of the acquisition of Viatris by Meda Pharma in 2005? At that time Viatris was a small company, and there…
Michael Krebs, managing director of the Institute of Molecular Biotechnology (IMBA), the leading publicly funded non-university biomedical research organization in Austria, provides an overview of IMBA’s role in the Austrian…
Christina Nageler, managing director of the Austrian Self Care Association (IGEPHA), the representative voice of the Austrian OTC community, provides an insight into the obstacles associated with the sale of…
Wolfgang Jank, general manager and founder, and Tina Theuer, managing partner, of first pharma J.M.T. GmbH, a young Austrian pharmaceutical service company, discuss the challenges of founding a new business…
Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well…
Prof. Johannes Khinast, CEO and scientific director, and Dr. Thomas Klein, CEO and business director of the Research Center Pharmaceutical Engineering, or RCPE, the world’s first pharmaceutical engineering company that…
Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and…
Sylvia Hofinger, director general of the Association of the chemical industry of Austria (FCIO), the representing voice of the Austrian chemical industry, discusses the drug pricing regulations that are affecting…
Karsten Schlemm MD, CEO of Merz Pharma Austria, a leading international German based aesthetic company, provides an in-depth look into the company´s transformation from pharmaceuticals to the aesthetics sector as…
Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles…
Herwig Ostermann, executive director of the Austrian Public Health Institute (GOeG), a neutral entity that brings expertise and evidence together to help plan and promote Austrian healthcare, provides insights into…
Dr. Erwin Klein, CEO and co-founder of easypharm, a generics and OTC company founded by Austrians for Austria, provides an overview of his exciting entrepreneurial experience and the challenges associated…
Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as…
See our Cookie Privacy Policy Here